Oncoinvent, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the successful enrollment of the sixth patient into the safety lead-in ...

Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced ...

KI has been awarded grants for eight postdoc research posts under Marie Skłodowska-Curie Actions (MSCA), the EU's flagship programme to promote ...

Uterine cancer (also known as endometrial cancer) is the fourth most common cancer women in the U.S. are diagnosed with. It primarily affects post-menopausal women and the average age of diagnosis is ...

In connection with the release of the results for the full year and fourth quarter 2024, Oncoinvent invites to the following events: Release of stock exchange notification. Press release, quarterly ...